Related Experiment Videos
Long-term course of interferon-treated chronic hepatitis C
C Cammà1, V Di Marco, O Lo Iacono
1Istituto Metodologie Diagnostiche Avanzate, Consiglio Nazionale delle Ricerche, Palermo, Italy.
Journal of Hepatology
|May 5, 1998
Summary
Sustained response to alpha-interferon therapy in chronic hepatitis C patients significantly improves clinical outcomes. Achieving sustained virologic response prevents liver disease progression and enhances event-free survival.
Area of Science:
- Hepatology
- Viral Hepatitis
- Immunotherapy
Background:
- Chronic hepatitis C poses a significant risk for liver disease progression.
- Alpha-interferon is a key treatment modality for chronic hepatitis C.
- Evaluating sustained response is crucial for understanding long-term treatment efficacy.
Purpose of the Study:
- To determine if sustained response to alpha-interferon improves clinical outcomes in chronic hepatitis C patients.
- To assess the long-term impact of sustained virologic response on liver disease progression.
Main Methods:
- A cohort of 410 patients with chronic hepatitis C were treated with alpha-interferon (a-2b or a-nl).
- Sustained response was defined as normal aminotransferases 12 months post-treatment.
- Patients were followed for a mean of 62.1 months (range 7-109 months).
Main Results:
- 15.1% of patients achieved sustained response (n=62).
- Sustained responders showed significantly longer event-free survival compared to non-responders.
- Absence of cirrhosis, younger age, and sustained response were independent predictors of improved survival.
Conclusions:
- Sustained response to alpha-interferon is associated with excellent long-term clinical outcomes in chronic hepatitis C.
- Hepatitis C virus (HCV) eradication and prevention of liver disease progression are likely in sustained responders.
- This highlights the importance of achieving sustained virologic response for managing chronic hepatitis C.